[go: up one dir, main page]

WO2008108309A1 - Dérivé de pyridine fusionné - Google Patents

Dérivé de pyridine fusionné Download PDF

Info

Publication number
WO2008108309A1
WO2008108309A1 PCT/JP2008/053692 JP2008053692W WO2008108309A1 WO 2008108309 A1 WO2008108309 A1 WO 2008108309A1 JP 2008053692 W JP2008053692 W JP 2008053692W WO 2008108309 A1 WO2008108309 A1 WO 2008108309A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridine derivative
fused pyridine
formula
fused
symbols
Prior art date
Application number
PCT/JP2008/053692
Other languages
English (en)
Japanese (ja)
Inventor
Atsuko Sato
Mariko Osakada
Kimihisa Ueno
Mirai Mizutani
Daisuke Harada
Katsuya Kobayashi
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Priority to JP2009502564A priority Critical patent/JPWO2008108309A1/ja
Publication of WO2008108309A1 publication Critical patent/WO2008108309A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention porte sur un dérivé de pyridine fusionné représenté par la formule (I) ci-dessous ou sur un sel pharmaceutiquement acceptable de celui-ci. (Dans la formule, les symboles sont tels que définis dans la description).
PCT/JP2008/053692 2007-03-02 2008-02-29 Dérivé de pyridine fusionné WO2008108309A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009502564A JPWO2008108309A1 (ja) 2007-03-02 2008-02-29 縮環ピリジン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007052361 2007-03-02
JP2007-052361 2007-03-02

Publications (1)

Publication Number Publication Date
WO2008108309A1 true WO2008108309A1 (fr) 2008-09-12

Family

ID=39738191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053692 WO2008108309A1 (fr) 2007-03-02 2008-02-29 Dérivé de pyridine fusionné

Country Status (3)

Country Link
JP (1) JPWO2008108309A1 (fr)
TW (1) TW200900408A (fr)
WO (1) WO2008108309A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041591A1 (fr) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Dérivé de pyridine fusionnée
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2021009365A1 (fr) * 2019-07-18 2021-01-21 Ctxt Pty Limited Dérivés de benzothiophène, de thiénopyridine et de thiénopyrimidine pour la modulation de sting
WO2021009362A1 (fr) * 2019-07-18 2021-01-21 Ctxt Pty Limited Dérivés de benzothiophène, de thiénopyridine et de thiénopyrimidine permettant la modulation d'une piqûre

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051587A1 (fr) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
WO2002012189A1 (fr) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Composes amide bicycliques condenses et utilisations medicales associees
JP2003530393A (ja) * 2000-04-08 2003-10-14 アストラゼネカ・アクチエボラーグ 化学化合物
JP2005104838A (ja) * 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
WO2005113560A2 (fr) * 2004-05-14 2005-12-01 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles utilises en tant qu'inhibiteurs de la proteine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051587A1 (fr) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
JP2003530393A (ja) * 2000-04-08 2003-10-14 アストラゼネカ・アクチエボラーグ 化学化合物
WO2002012189A1 (fr) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Composes amide bicycliques condenses et utilisations medicales associees
JP2005104838A (ja) * 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
WO2005113560A2 (fr) * 2004-05-14 2005-12-01 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles utilises en tant qu'inhibiteurs de la proteine kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DORSEY, BRUCE D. ET AL.: "Identification of MK-944a: A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 18, 2000, pages 3386 - 3399, XP002564479 *
WYATT, PAUL G. ET AL.: "Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 10, 2002, pages 1405 - 1411, XP055352034 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041591A1 (fr) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Dérivé de pyridine fusionnée
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2021009365A1 (fr) * 2019-07-18 2021-01-21 Ctxt Pty Limited Dérivés de benzothiophène, de thiénopyridine et de thiénopyrimidine pour la modulation de sting
WO2021009362A1 (fr) * 2019-07-18 2021-01-21 Ctxt Pty Limited Dérivés de benzothiophène, de thiénopyridine et de thiénopyrimidine permettant la modulation d'une piqûre
CN114206882A (zh) * 2019-07-18 2022-03-18 Ctxt私人有限公司 用于调节sting的苯并噻吩、噻吩并吡啶和噻吩并嘧啶衍生物
CN114206880A (zh) * 2019-07-18 2022-03-18 Ctxt私人有限公司 用于调节sting的苯并噻吩、噻吩并吡啶和噻吩并嘧啶衍生物
JP2022541044A (ja) * 2019-07-18 2022-09-21 シーティーエックスティー・ピーティーワイ・リミテッド Ｓｔｉｎｇのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体
JP2022541043A (ja) * 2019-07-18 2022-09-21 シーティーエックスティー・ピーティーワイ・リミテッド Ｓｔｉｎｇのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体
CN114206882B (zh) * 2019-07-18 2024-11-12 Ctxt私人有限公司 用于调节sting的苯并噻吩、噻吩并吡啶和噻吩并嘧啶衍生物
CN114206880B (zh) * 2019-07-18 2024-12-06 Ctxt私人有限公司 用于调节sting的苯并噻吩、噻吩并吡啶和噻吩并嘧啶衍生物
JP7607627B2 (ja) 2019-07-18 2024-12-27 シーティーエックスティー・ピーティーワイ・リミテッド Ｓｔｉｎｇのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体
JP7607626B2 (ja) 2019-07-18 2024-12-27 シーティーエックスティー・ピーティーワイ・リミテッド Ｓｔｉｎｇのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体

Also Published As

Publication number Publication date
JPWO2008108309A1 (ja) 2010-06-17
TW200900408A (en) 2009-01-01

Similar Documents

Publication Publication Date Title
IL201973A0 (en) 3,3-spiroindolinone derivatives
WO2008110355A8 (fr) Dérivés de quinoléine en tant que fongicides
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
SI2334687T1 (sl) Dioksa biciklo oktan triol derivati
WO2009030469A8 (fr) Nouveaux fongicides
EP1889848B8 (fr) Dérivé de morphinane substitué par un carbamoyle en position 7 et ayant une insauration en position 6,7
WO2009019015A8 (fr) Nouveaux herbicides
WO2009074875A8 (fr) Panneaux résistants, absorbant le son et leur procédé de fabrication
WO2010015657A3 (fr) Nouveaux alcoxypyrazoles
ZA201002217B (en) 1,3-dihydroisoindole derivatives
WO2010065318A3 (fr) Tamis moléculaire ssz-83
SI2373660T1 (sl) 3,6-disubstituirane ksantilijeve soli kot zdravila
WO2006081515A3 (fr) Polymorphes d'hydrochlorure de duloxetine
WO2010059297A3 (fr) Procédés utilisant le tamis moléculaire ssz-82
WO2009055289A3 (fr) Lactames substitués à usage thérapeutique
MY157497A (en) Pyrazinooxazepine derivatives
AU2009216062A8 (en) Novel aminopyridine derivatives having Aurora A selective inhibitory action
DK2203457T3 (da) Dispiro-1,2,4-trioxolaner som antimalariamidler
WO2010120058A3 (fr) Nouveau composé cyanine destiné au marquage de biomolécules et son procédé de préparation
IL202093A0 (en) 4,4-disubstituted piperidine derivatives
WO2009022327A3 (fr) Nouveau procédé de préparation de lévocétirizine de pureté élevée et de ses sels
PL1992622T3 (pl) Pochodna 4-(3-benzoiloaminofenylo)-6,7-dimetoksy-2-metyloaminochinazoliny
WO2007148102A3 (fr) Hydrochlorure crystallin de duloxétine
WO2008108309A1 (fr) Dérivé de pyridine fusionné

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721112

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009502564

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08721112

Country of ref document: EP

Kind code of ref document: A1